Intriguingly, PRL-3 was recently reported as a possible downstream target of FLT3-ITD signalling, with a potential role in drug resistance of leukaemia cells (Zhou et al, 2011), indicating that PRL-3 expression levels could be an important factor contributing to the outcomes of the AML treatments. The gene discussed is FLT3; the disease is acute myeloid leukemia.